SEC Form 4 · accession 0001209191-17-045120

ChemoCentryx, Inc. · CCXI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Medical Officer

Period of report

Jul 11, 2017

Accepted (ET)

Jul 13, 2017 · 7:46 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001340652

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Jul 11, 2017	M	6,124	$6.30	A	65,963	D
Common Stock	Jul 11, 2017	S	6,124	$9.30	D	59,839	D
Common Stock	Jul 11, 2017	M	23,876	$6.90	A	83,715	D
Common Stock	Jul 11, 2017	S	23,876	$9.90	D	59,839	D
Common Stock	Jul 12, 2017	M	10,000	$6.00	A	69,839	D
Common Stock	Jul 12, 2017	S	10,000	$10.00	D	59,839	D
Common Stock	Jul 12, 2017	M	1,250	$6.30	A	61,089	D
Common Stock	Jul 12, 2017	S	1,250	$10.00	D	59,839	D
Common Stock	Jul 12, 2017	M	9,253	$6.90	A	69,092	D
Common Stock^F2	Jul 12, 2017	S	9,253	$9.9222	D	59,839	D
Common Stock	Jul 12, 2017	M	6,997	$7.10	A	66,836	D
Common Stock	Jul 12, 2017	S	6,997	$10.00	D	59,839	D
Common Stock	Jul 12, 2017	M	2,500	$8.19	A	62,339	D
Common Stock	Jul 12, 2017	S	2,500	$10.00	D	59,839	D
Common Stock	Jul 13, 2017	M	3,888	$7.10	A	63,727	D
Common Stock	Jul 13, 2017	S	3,888	$10.28	D	59,839	D
Common Stock	Jul 13, 2017	M	12,125	$8.19	A	71,964	D
Common Stock^F3	Jul 13, 2017	S	12,125	$10.1852	D	59,839	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F5,F4	$6.30	Jul 11, 2017	M	6,124	D	—	Aug 10, 2020	Common Stock	6,124	3,750	D
Stock Option (right to buy)^F5,F4	$6.90	Jul 11, 2017	M	23,876	D	—	Aug 4, 2021	Common Stock	23,876	13,345	D
Stock Option (right to buy)^F5,F4	$6.00	Jul 12, 2017	M	10,000	D	—	Feb 17, 2019	Common Stock	10,000	0	D
Stock Option (right to buy)^F5,F4	$6.30	Jul 12, 2017	M	1,250	D	—	Aug 10, 2020	Common Stock	1,250	2,500	D
Stock Option (right to buy)^F5,F4	$6.90	Jul 12, 2017	M	9,253	D	—	Aug 4, 2021	Common Stock	9,253	4,092	D
Stock Option (right to buy)^F5,F4	$7.10	Jul 12, 2017	M	6,997	D	—	Feb 19, 2024	Common Stock	6,997	135,503	D
Stock Option (right to buy)^F5,F4	$8.19	Jul 12, 2017	M	2,500	D	—	Feb 23, 2025	Common Stock	2,500	191,500	D
Stock Option (right to buy)^F5,F4	$7.10	Jul 13, 2017	M	3,888	D	—	Feb 19, 2024	Common Stock	3,888	131,615	D
Stock Option (right to buy)^F5,F4	$8.19	Jul 13, 2017	M	12,125	D	—	Feb 23, 2025	Common Stock	12,125	179,375	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from $9.90 to $10.00 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
F3Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from $10.00 to $10.37 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
F4As of July 11, 2017, and prior to this transaction, the exercised options were fully vested.
F5Not applicable.